Technical Note: Dosimetric impact of spherical applicator size in Intrabeam™ IORT for treating unicentric breast cancer lesions

Saleh, Yaseen; Zhang, Hualin

doi:10.1002/mp.12637

Cited by 9 publications

(10 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tissues and vital organs are therefore protected from radiation. Intrabeam technology progressed rapidly in recent years and is widely used in the treatment of breast cancer [20], brain tumor [11], metastatic spinal cord cancer [21], and rectal cancer [12]. Its advantages are as follows: (i) The treatment time is short, which greatly shortens the interval between surgery and other treatment methods and overall treatment time.…”

Section: Discussionmentioning

confidence: 99%

A Novel Radiotherapy Approach for Keloids with Intrabeam

Yang

Shao

et al. 2019

BioMed Research International

View full text Add to dashboard Cite

Background. Keloids are hard nodules or plaques formed by excessive proliferation of connective tissue. Radiotherapy, widely used in various benign and malignant skin diseases, is an effective treatment for keloids. This work evaluates Intrabeam photon radiotherapy in the management of keloids. Methods. Fourteen patients who have undergone Intrabeam radiotherapy for a total of 15 sites of keloids were followed up. Twelve cases were first onset and the other two had recurrent diseases. Thirteen patients underwent surgical resection of keloids before radiotherapy. One relapsing patient received only 2 rounds of radiation therapy as she could not be reoperated. Radiotherapy was divided into 2 sessions on days 0 and 3 after surgery. The dose was 4 or 5 Gy each time for 3 min 14 s to 12 min 1 s. In addition, we compared our data to the recurrence of keloids in fourteen patients who had previously been exposed to electron beam using conventional accelerators. Results. We analyzed the treatment for adverse reactions and recurrence. In the Intrabeam group, one patient developed superficial skin ulcers a month after treatment. No one experienced wound rupture, bleeding, infection, skin contractures, or obvious hyperpigmentation. None of the fourteen cases showed any recurrence so far after on median 22.5 months of follow-up. Five patients in the electron beam group relapsed 3 to 10 months after treatment. Conclusion. Here, Intrabeam photon radiotherapy was shown to be an effective treatment for keloid scars and it is therefore recommended for management of this disease.

show abstract

Section: Discussionmentioning

confidence: 99%

A Novel Radiotherapy Approach for Keloids with Intrabeam

Yang

Shao

et al. 2019

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…The dose-rate as a function of the depth around the XRS is characterized to commission a new source in the clinical treatment planning system. Figure 4 presents the output characteristics for 15 XRSs on a logarithmic scale for 40-kVp and 50-kVp energies. The dose gradient near the XRS is very steep; thus, the separation between the parallel-plate ionization chamber and x-ray source must be known to high accuracy.…”

Section: Resultsmentioning

confidence: 99%

“…This work presents a mean of the DDCs, which can assist investigators in performing ancillary research. For example, investigators have attempted to calculate relative biological effectiveness and equivalent uniform dose using beam data from a single XRS. These studies could benefit from the analysis performed on a mean dataset, which is not biased by individual source data and is a more robust representation of the delivered doses to patients treated with this device.…”

Section: Discussionmentioning

confidence: 99%

“…The ATF tables are advantageous because the XRSs can be interchanged without the DDCs being remeasured . Several investigators have used the ATF tables to estimate the dose‐rate and dose distribution in the vicinity of the spherical applicator …”

Section: Methodsmentioning

confidence: 99%

“…12,13 Several investigators have used the ATF tables to estimate the dose-rate and dose distribution in the vicinity of the spherical applicator. [15][16][17] Figure 3 illustrates the self-shielded water phantom provided by Zeiss for users to validate the factory calibration. In this phantom,…”

Section: A | Device Descriptionmentioning

confidence: 99%

See 2 more Smart Citations

Evaluation of the dosimetric impact of manufacturing variations for the INTRABEAM x‐ray source

Shaikh¹,

Joiner

Nalichowski

et al. 2020

J Applied Clin Med Phys

View full text Add to dashboard Cite

Introduction INTRABEAM x‐ray sources (XRSs) have distinct output characteristics due to subtle variations between the ideal and manufactured products. The objective of this study is to intercompare 15 XRSs and to dosimetrically quantify the impact of manufacturing variations on the delivered dose. Methods and Materials The normality of the XRS datasets was evaluated with the Shapiro–Wilk test, the accuracy of the calibrated depth–dose curves (DDCs) was validated with ionization chamber measurements, and the shape of each DDC was evaluated using depth–dose ratios (DDRs). For 20 Gy prescribed to the spherical applicator surface, the dose was computed at 5‐mm and 10‐mm depths from the spherical applicator surface for all XRSs. Results At 5‐, 10‐, 20‐, and 30‐mm depths from the source, the coefficient of variation (CV) of the XRS output for 40 kVp was 4.4%, 2.8%, 2.0%, and 3.1% and for 50 kVp was 4.2%, 3.8%, 3.8%, and 3.4%, respectively. At a 20‐mm depth from the source, the 40‐kVp energy had a mean output in Gy/Minute = 0.36, standard deviation (SD) = 0.0072, minimum output = 0.34, and maximum output = 0.37 and a 50‐kVp energy had a mean output = 0.56, SD = 0.021, minimum output = 0.52, and maximum output = 0.60. We noted the maximum DRR values of 2.8% and 2.5% for 40 kVp and 50 kVp, respectively. For all XRSs, the maximum dosimetric effect of these variations within a 10‐mm depth of the applicator surface is ≤ 2.5%. The CV increased as depth increased and as applicator size decreased. Conclusion The American Association of Physicist in Medicine Task Group‐167 requires that the impurities in radionuclides used for brachytherapy produce ≤ 5.0% dosimetric variations. Because of differences in an XRS output and DDC, we have demonstrated the dosimetric variations within a 10‐mm depth of the applicator surface to be ≤ 2.5%.

show abstract

Primary study of the relative and compound biological effectiveness model for boron neutron capture therapy based on nanodosimetry

Mao,

Zhang,

Luo

et al. 2024

Medical Physics

View full text Add to dashboard Cite

BackgroundThe current radiobiological model employed for boron neutron capture therapy (BNCT) treatment planning, which relies on microdosimetry, fails to provide an accurate representation the biological effects of BNCT. The precision in calculating the relative biological effectiveness (RBE) and compound biological effectiveness (CBE) plays a pivotal role in determining the therapeutic efficacy of BNCT. Therefore, this study focuses on how to improve the accuracy of the biological effects of BNCT.PurposeThe purpose of this study is to propose new radiation biology models based on nanodosimetry to accurately assess RBE and CBE for BNCT.MethodsNanodosimetry, rooted in ionization cluster size distributions (ICSD), introduces a novel approach to characterize radiation quality by effectively delineating RBE through the ion track structure at the nanoscale. In the context of prior research, this study presents a computational model for the nanoscale assessment of RBE and CBE. We establish a simplified model of DNA chromatin fiber using the Monte Carlo code TOPAS‐nBio to evaluate the applicability of ICSD to BNCT and compute nanodosimetric parameters.ResultsOur investigation reveals that both homogeneous and heterogeneous nanodosimetric parameters, as well as the corresponding biological model coefficients α and β, along with RBE values, exhibit variations in response to varying intracellular 10B concentrations. Notably, the nanodosimetric parameter effectively captures the fluctuations in model coefficients α and RBE.ConclusionOur model facilitates a nanoscale analysis of BNCT, enabling predictions of nanodosimetric quantities for secondary ions as well as RBE, CBE, and other essential biological metrics related to the distribution of boron. This contribution significantly enhances the precision of RBE calculations and holds substantial promise for future applications in treatment planning.

show abstract

Technical Note: Dosimetric impact of spherical applicator size in Intrabeam™ IORT for treating unicentric breast cancer lesions

Cited by 9 publications

References 21 publications

A Novel Radiotherapy Approach for Keloids with Intrabeam

A Novel Radiotherapy Approach for Keloids with Intrabeam

Evaluation of the dosimetric impact of manufacturing variations for the INTRABEAM x‐ray source

Primary study of the relative and compound biological effectiveness model for boron neutron capture therapy based on nanodosimetry

Contact Info

Product

Resources

About